{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:53:20Z","timestamp":1792612400109,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ebiom.2019.03.027","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T09:54:57Z","timestamp":1552902897000},"page":"225-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Jingyan","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijue","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pixu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2019.03.027_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.027_bb0010","first-page":"69","article-title":"Cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ebiom.2019.03.027_bb0015","first-page":"277","article-title":"Cancer statistics, 2016","volume":"60","author":"Siegel","year":"2010","journal-title":"CA Cancer J. Clin"},{"issue":"9","key":"10.1016\/j.ebiom.2019.03.027_bb0020","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic Cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ebiom.2019.03.027_bb0025","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"6330","key":"10.1016\/j.ebiom.2019.03.027_bb0030","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ebiom.2019.03.027_bb0035","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Cancer genome atlas research network: integrated genomic analyses of ovarian carcinoma","volume":"474","author":"TCGA","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ebiom.2019.03.027_bb0045","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian Cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ebiom.2019.03.027_bb0050","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.ebiom.2019.03.027_bb0055","first-page":"123","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Nc","year":"2009","journal-title":"New England J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.027_bb0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2019.03.027_bb0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","article-title":"Synthetic lethality and Cancer therapy: lessons learned from the development of PARP inhibitors","volume":"66","author":"Lord","year":"2015","journal-title":"Annu Rev Med"},{"issue":"9","key":"10.1016\/j.ebiom.2019.03.027_bb0070","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ebiom.2019.03.027_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2019.03.027_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 inhibitors: the mechanism of action May not be as simple as once thought","volume":"34","author":"ME","year":"2018","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.ebiom.2019.03.027_bb0085","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.027_bb0090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.ebiom.2019.03.027_bb0095","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.ebiom.2019.03.027_bb0100","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-14-3763","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method--letter","volume":"75","author":"Ashton","year":"2015","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.027_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","article-title":"Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells","volume":"21","author":"Muranen","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1385\/1-59259-973-7:275","article-title":"The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair","volume":"314","author":"Speit","year":"2006","journal-title":"Methods Mol Biol"},{"issue":"10","key":"10.1016\/j.ebiom.2019.03.027_bb0115","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.embor.7400255","article-title":"DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells","volume":"5","author":"Gudmundsdottir","year":"2004","journal-title":"EMBO Rep"},{"issue":"13","key":"10.1016\/j.ebiom.2019.03.027_bb0120","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1158\/0008-5472.CAN-15-2304","article-title":"Three-dimensional breast Cancer models mimic hallmarks of size-induced tumor progression","volume":"76","author":"Singh","year":"2016","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.ebiom.2019.03.027_bb0125","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1073\/pnas.94.13.6658","article-title":"C-Myc transactivation of LDH-A: implications for tumor metabolism and growth","volume":"94","author":"Shim","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.ebiom.2019.03.027_bb0130","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ebiom.2019.03.027_bb0135","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ncb1110","article-title":"A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells","volume":"6","author":"Yeh","year":"2004","journal-title":"Nat Cell Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2019.03.027_bb0140","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2011.555","article-title":"Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours","volume":"106","author":"Dean","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2019.03.027_bb0145","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/13543784.2016.1156857","article-title":"Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer","volume":"25","author":"Ivy","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.ebiom.2019.03.027_bb0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Brown","year":"2017","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ebiom.2019.03.027_bb0155","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian Cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.ebiom.2019.03.027_bb0160","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast Cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.ebiom.2019.03.027_bb0165","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ebiom.2019.03.027_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/onc.2017.326","article-title":"PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy","volume":"37","author":"Bian","year":"2018","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.ebiom.2019.03.027_bb0175","article-title":"Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer","volume":"7","author":"Dong","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.ebiom.2019.03.027_bb0180","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.18632\/oncotarget.1929","article-title":"Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells","volume":"5","author":"Choi","year":"2014","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ebiom.2019.03.027_bb0185","first-page":"3097","article-title":"Targeting the ATR\/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian Cancer models","volume":"145","author":"Kim","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","article-title":"PARP inhibitor combination therapy","volume":"108","author":"Dr\u00e9an","year":"2016","journal-title":"Crit Rev Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.03.027_bb0195","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ebiom.2019.03.027_bb0200","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djs002","article-title":"Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy","volume":"104","author":"Roberts","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ebiom.2019.03.027_bb0205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1097-2765(02)00520-8","article-title":"c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability","volume":"9","author":"Vafa","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0210","series-title":"c-Myc, genome instability, and tumorigenesis: The devil is in the details","author":"Wade","year":"2006"},{"issue":"9","key":"10.1016\/j.ebiom.2019.03.027_bb0215","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.4161\/cc.6.9.4161","article-title":"The ever expanding role for c-Myc in promoting genomic instability","volume":"6","author":"Prochownik","year":"2007","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.ebiom.2019.03.027_bb0220","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ebiom.2019.03.027_bb0225","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer","volume":"78","author":"Carey","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0230","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.mrfmmm.2015.02.005","article-title":"MYC impairs resolution of site-specific DNA double-strand breaks repair","volume":"774","author":"Ambrosio","year":"2015","journal-title":"Mutat Res"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0235","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1471-2407-11-246","article-title":"c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.ebiom.2019.03.027_bb0240","doi-asserted-by":"crossref","first-page":"14446","DOI":"10.1074\/jbc.M511914200","article-title":"Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity","volume":"281","author":"Jin","year":"2006","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.027_bb0245","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jmcb\/mjr046","article-title":"Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair","volume":"4","author":"Song","year":"2012","journal-title":"J Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.ebiom.2019.03.027_bb0250","doi-asserted-by":"crossref","DOI":"10.1593\/neo.121258","article-title":"c-Myc suppression of DNA double-strand break repair 1 2","volume":"14","author":"Li","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2017.12.037","article-title":"A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer","volume":"417","author":"Lee","year":"2018","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.ebiom.2019.03.027_bb0260","doi-asserted-by":"crossref","first-page":"940","DOI":"10.15252\/msb.20167321","article-title":"De novo MYC addiction as an adaptive response of cancer cells to CDK4\/6 inhibition","volume":"13","author":"Tarrado-Castellarnau","year":"2017","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.ebiom.2019.03.027_bb0265","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ebiom.2019.03.027_bb0270","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.celrep.2018.10.096","article-title":"Integrated genomic, Epigenomic, and expression analyses of ovarian Cancer cell lines","volume":"25","author":"Papp","year":"2018","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.ebiom.2019.03.027_bb0275","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1535-7163.MCT-14-0801","article-title":"Targeting c-MYC in platinum-resistant ovarian Cancer","volume":"14","author":"Reyes-Gonzalez","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419301677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419301677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:57:35Z","timestamp":1762455455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419301677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":55,"alternative-id":["S2352396419301677"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.027","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}